VA Dod Clinical Practice Guideline for the Management of Pregnancy

Total Page:16

File Type:pdf, Size:1020Kb

VA Dod Clinical Practice Guideline for the Management of Pregnancy VA/DOD CLINICAL PRACTICE GUIDELINE FOR THE MANAGEMENT OF PREGNANCY Department of Veterans Affairs Department of Defense QUALIFYING STATEMENTS The Department of Veterans Affairs and the Department of Defense guidelines are based upon the best information available at the time of publication. They are designed to provide information and assist decision making. They are not intended to define a standard of care and should not be construed as one. Neither should they be interpreted as prescribing an exclusive course of management. This Clinical Practice Guideline is based on a systematic review of both clinical and epidemiological evidence. Developed by a panel of multidisciplinary experts, it provides a clear explanation of the logical relationships between various care options and health outcomes while rating both the quality of the evidence and the strength of the recommendation. Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional making use of these guidelines is responsible for evaluating the appropriateness of applying them in the setting of any particular clinical situation. These guidelines are not intended to represent Department of Veterans Affairs or TRICARE policy. Further, inclusion of recommendations for specific testing and/or therapeutic interventions within these guidelines does not guarantee coverage of civilian sector care. Additional information on current TRICARE benefits may be found at www.tricare.mil or by contacting your regional TRICARE Managed Care Support Contractor. Version 3.0 – 2018 VA/DoD Clinical Practice Guideline for the Management of Pregnancy Prepared by: The Management of Pregnancy Work Group With support from: The Office of Quality, Safety and Value, VA, Washington, DC & Office of Evidence Based Practice, U.S. Army Medical Command Version 3.0 – 2018 Based on evidence reviewed through May 2017 March 2018 Page 2 of 147 VA/DoD Clinical Practice Guideline for the Management of Pregnancy Table of Contents I. Introduction ..................................................................................................................................... 6 II. Background...................................................................................................................................... 6 A. Description of Pregnancy .................................................................................................................... 6 B. Epidemiology and Impact in the General Population ........................................................................ 7 a. Rates of Reproduction ................................................................................................................. 7 b. Pregnancy Complications ............................................................................................................ 7 C. Pregnancy in the Department of Defense and the Department of Veterans Affairs Populations ... 8 a. Location of Care ........................................................................................................................... 8 b. Rates of Reproduction ................................................................................................................. 9 c. Complications .............................................................................................................................. 9 III. About this Clinical Practice Guideline ............................................................................................. 10 A. Methods ............................................................................................................................................. 10 a. Grading Recommendations ....................................................................................................... 11 b. Reconciling 2009 Clinical Practice Guideline Recommendations ............................................. 13 c. Peer Review Process .................................................................................................................. 14 B. Summary of Patient Focus Group Methods and Findings ................................................................ 14 C. Conflicts of Interest ........................................................................................................................... 15 D. Scope of this Clinical Practice Guideline ........................................................................................... 16 E. Highlighted Features of this Clinical Practice Guideline ................................................................... 16 F. Patient-centered Care ....................................................................................................................... 16 G. Shared Decision Making .................................................................................................................... 17 H. Co-occurring Conditions .................................................................................................................... 17 I. Implementation ................................................................................................................................. 18 IV. Guideline Work Group ................................................................................................................... 19 V. Algorithm ...................................................................................................................................... 20 A. Algorithm Key .................................................................................................................................... 21 B. Actions at Every Visit ......................................................................................................................... 21 C. Interventions by Weeks Gestation .................................................................................................... 21 D. Standard of Pregnancy Care .............................................................................................................. 23 a. Additional Information on Actions at Every Visit ...................................................................... 23 b. Screenings .................................................................................................................................. 24 c. Time Sensitive Care .................................................................................................................... 28 d. Summary .................................................................................................................................... 28 March 2018 Page 3 of 147 VA/DoD Clinical Practice Guideline for the Management of Pregnancy VI. Routine Pregnancy Care ................................................................................................................. 29 VII. Recommendations ......................................................................................................................... 33 A. Care Throughout Pregnancy .............................................................................................................. 36 a. Routine Care During Pregnancy ................................................................................................ 36 b. Nutrition ..................................................................................................................................... 39 c. Screening .................................................................................................................................... 40 d. Education ................................................................................................................................... 43 B. One-time Interventions ..................................................................................................................... 44 a. Screening and Diagnostic Testing ............................................................................................. 44 b. Imaging ...................................................................................................................................... 49 c. Preparing for Delivery ................................................................................................................ 50 d. Postpartum Care ........................................................................................................................ 51 C. Referral ............................................................................................................................................... 52 D. Special Considerations ....................................................................................................................... 55 a. High Risk for Preeclampsia ........................................................................................................ 55 b. High Risk for Preterm Delivery .................................................................................................. 56 c. Over 44 Years of Age ................................................................................................................. 57 d. History of Bariatric Surgery ....................................................................................................... 58 Appendix A: Evidence Review Methodology ......................................................................................
Recommended publications
  • The Diagnostic Impact of Limited, Screening Obstetric Ultrasound When Performed by Midwives in Rural Uganda
    Journal of Perinatology (2014) 34, 508–512 © 2014 Nature America, Inc. All rights reserved 0743-8346/14 www.nature.com/jp ORIGINAL ARTICLE The diagnostic impact of limited, screening obstetric ultrasound when performed by midwives in rural Uganda JO Swanson1, MG Kawooya2, DL Swanson1, DS Hippe1, P Dungu-Matovu2 and R Nathan1 OBJECTIVE: To evaluate the diagnostic impact of limited obstetric ultrasound (US) in identifying high-risk pregnancies when used as a screening tool by midwives in rural Uganda. STUDY DESIGN: This was an institutional review board-approved prospective study of expecting mothers in rural Uganda who underwent clinical and US exams as part of their standard antenatal care visit in a local health center in the Isingiro district of Uganda. The midwives documented clinical impressions before performing a limited obstetric US on the same patient. The clinical findings were then compared with the subsequent US findings to determine the diagnostic impact. The midwives were US-naive before participating in the 6-week training course for limited obstetric US. RESULT: Midwife-performed screening obstetric US altered the clinical diagnosis in up to 12% clinical encounters. This diagnostic impact is less (6.7 to 7.4%) if the early third trimester diagnosis of malpresentation is excluded. The quality assurance review of midwives’ imaging demonstrated 100% sensitivity and specificity in the diagnosing gestational number, and 90% sensitivity and 96% specificity in the diagnosis of fetal presentation. CONCLUSION: Limited, screening obstetric US performed by midwives with focused, obstetric US training demonstrates the diagnostic impact for identifying conditions associated with high-risk pregnancies in 6.7 to 12% of patients screened.
    [Show full text]
  • Breech Presentation at Delivery: a Marker for Congenital Anomaly?
    Journal of Perinatology (2014) 34, 11–15 & 2014 Nature America, Inc. All rights reserved 0743-8346/14 www.nature.com/jp ORIGINAL ARTICLE Breech presentation at delivery: a marker for congenital anomaly? D Mostello1, JJ Chang2, F Bai2, J Wang3, C Guild4, K Stamps2 and TL Leet2,{ OBJECTIVE: To determine whether congenital anomalies are associated with breech presentation at the time of birth. STUDY DESIGN: A population-based, retrospective cohort study was conducted among 460 147 women with singleton live births using the Missouri Birth Defects Registry, which includes all defects diagnosed during the first year of life. Maternal and obstetric characteristics and outcomes between breech and cephalic presentation groups were compared using w2-square statistic and Student’s t-test. Multivariable binary logistic regression analysis was used to estimate adjusted odds ratios (aORs) and 95% confidence intervals (CIs). RESULT: At least one congenital anomaly was more likely present among infants breech at birth (11.7%) than in those with cephalic presentation (5.1%), whether full-term (9.4 vs 4.6%) or preterm (20.1 vs 11.6%). The relationship between breech presentation and congenital anomaly was stronger among full-term births (aOR 2.09, CI 1.96, 2.23, term vs 1.40, CI 1.26, 1.55, preterm), but not in all categories of anomalies. CONCLUSION: Breech presentation at delivery is a marker for the presence of congenital anomaly. Infants delivered breech deserve special scrutiny for the presence of malformation. Journal of Perinatology (2014) 34, 11–15;
    [Show full text]
  • A Guide to Obstetrical Coding Production of This Document Is Made Possible by Financial Contributions from Health Canada and Provincial and Territorial Governments
    ICD-10-CA | CCI A Guide to Obstetrical Coding Production of this document is made possible by financial contributions from Health Canada and provincial and territorial governments. The views expressed herein do not necessarily represent the views of Health Canada or any provincial or territorial government. Unless otherwise indicated, this product uses data provided by Canada’s provinces and territories. All rights reserved. The contents of this publication may be reproduced unaltered, in whole or in part and by any means, solely for non-commercial purposes, provided that the Canadian Institute for Health Information is properly and fully acknowledged as the copyright owner. Any reproduction or use of this publication or its contents for any commercial purpose requires the prior written authorization of the Canadian Institute for Health Information. Reproduction or use that suggests endorsement by, or affiliation with, the Canadian Institute for Health Information is prohibited. For permission or information, please contact CIHI: Canadian Institute for Health Information 495 Richmond Road, Suite 600 Ottawa, Ontario K2A 4H6 Phone: 613-241-7860 Fax: 613-241-8120 www.cihi.ca [email protected] © 2018 Canadian Institute for Health Information Cette publication est aussi disponible en français sous le titre Guide de codification des données en obstétrique. Table of contents About CIHI ................................................................................................................................. 6 Chapter 1: Introduction ..............................................................................................................
    [Show full text]
  • Twin Pregnancy with Triploidy and Co-Existing Live Twin Progressing to Viability: Case Study and Literature Review
    Obstetrics & Gynecology International Journal Case Report Open Access Twin pregnancy with triploidy and co-existing live twin progressing to viability: Case study and literature review Abstract Volume 9 Issue 4 - 2018 Background: Twin pregnancies consisting of a triploid fetus with molar change and a 1,2 1,2 1,2 healthy coexisting fetus is an extremely rare phenomenon. Triploidy rarely advances to the Cingiloglu P, Yeung T, Sekar R second trimester, most resulting in a miscarriage, termination or stillbirth. Only five cases 1Royal Brisbane and Women’s Hospital, Women’s and Newborn of a triploid fetus and a healthy co-twin have been reported in literature. We present the first Services, Australia documented case of a live delivery of both triploid fetus and coexisting viable twin. 2University of Queensland, Australia Case presentation: A 23-year old woman, gravida 2, para 1 was admitted at 26+4 weeks Correspondence: Pinar Cingiloglu, Women’s and Newborn gestation with DCDA twins and a shortened cervix. Sonography revealed polyhydramnios, Services, Royal Brisbane and Women’s Hospital, Bowen Bridge an abnormal cystic placenta, and small aortic valve for the presenting twin. Emergency Road&, Butterfield St, Herston Queensland Australia, Tel +61 caesarean section was performed at 28 weeks gestation for cord prolapse. Twin A was born (07) 3646 8111, Email [email protected] a live infant with ambiguous genitalia, syndactyly, epicanthic folds and cerebral cysts. Twin B was born a healthy live male. Histopathology revealed features consistent with Received: June 13, 2018 | Published: July 13, 2018 partial hydatidiform mole, and cytogenetics revealed a diandric triploidy in twin A.
    [Show full text]
  • Gtg-No-20B-Breech-Presentation.Pdf
    Guideline No. 20b December 2006 THE MANAGEMENT OF BREECH PRESENTATION This is the third edition of the guideline originally published in 1999 and revised in 2001 under the same title. 1. Purpose and scope The aim of this guideline is to provide up-to-date information on methods of delivery for women with breech presentation. The scope is confined to decision making regarding the route of delivery and choice of various techniques used during delivery. It does not include antenatal or postnatal care. External cephalic version is the topic of a separate RCOG Green-top Guideline No. 20a: ECV and Reducing the Incidence of Breech Presentation. 2. Background The incidence of breech presentation decreases from about 20% at 28 weeks of gestation to 3–4% at term, as most babies turn spontaneously to the cephalic presentation. This appears to be an active process whereby a normally formed and active baby adopts the position of ‘best fit’ in a normal intrauterine space. Persistent breech presentation may be associated with abnormalities of the baby, the amniotic fluid volume, the placental localisation or the uterus. It may be due to an otherwise insignificant factor such as cornual placental position or it may apparently be due to chance. There is higher perinatal mortality and morbidity with breech than cephalic presentation, due principally to prematurity, congenital malformations and birth asphyxia or trauma.1,2 Caesarean section for breech presentation has been suggested as a way of reducing the associated perinatal problems2,3 and in many countries in Northern Europe and North America caesarean section has become the normal mode of breech delivery.
    [Show full text]
  • Efficacy of Genetic Testing in Cases of Ambiguous Genitalia
    EFFICACY OF GENETIC TESTING IN CASES OF AMBIGUOUS GENITALIA DETECTED ON PRENATAL! ULTRASOUND ! ! ! by! EVELYN ROSE! CRAWFORD ! ! Submitted in partial fulfillment of !the requirements for the degree of Master of! Science ! ! ! Thesis Advisor: Larisa! Baumanis, MS ! ! Genetic Counseling! Department !of Genetics CASE WESTERN RESERVE! UNIVERSITY ! ! ! ! ! ! ! August, 2014 ! ! CASE WESTERN RESERVE! UNIVERSITY SCHOOL OF GRADUATE! STUDIES We hereby approve! the thesis of: Evelyn Rose! Crawford candidate for the degree of !Master of Science degree.* ! ! Larisa Baumanis, MS (Committee Chair) ! Anne Matthews, RN, PhD ! Noam Lazebnik, MD ! Aditi Parikh, MD ! Sara Debanne, PhD ! ! ! ! Date of Defense June 20, 2014 ! ! ! ! ! *We also certify that written approval has been obtained for any proprietary material contained therein !2 ! ! ! TABLE OF CONTENTS List of Tables 4 List of Figures 5 Acknowledgements 6 Abstract 7 Introduction 8 Purpose of Study & Specific Aims 10 Background 11 Detection of Ambiguous Genitalia on Prenatal Ultrasound 11 Current use of Genetic testing in determining a specific diagnosis 13 The Importance of Prenatal Diagnosis in Cases of Ambiguous Genitalia 18 Significance for genetic counselors 19 Conclusions 20 Methodology 22 Systematic Review of the Literature 22 Chart Review 27 Algorithm & Analysis 29 Results 31 Analysis 52 Discussion 55 Appendix I: First Review Matrix Organization and summary of literature review articles 62 Appendix II: Second Review Matrix Organization and summary of case studies from the literature review 78 Appendix III: Third Review Matrix Organization and summary of chart review cases 94 References 102 !3 LIST OF TABLES ! !Table 1: Keyword Combinations for Literature Search 22 !Table 2: Example First Review Matrix 25 !Table 3: Example Second Review Matrix 25 !Table 4: Protocol Key 26 !Table 5: Example Third Review Matrix 29 Table 6: Imaging characteristics to differentiate cloacal exstrophy, bladder !exstrophy and cloacal malformation (Calvo-Garcia et al.
    [Show full text]
  • Advising Women with Diabetes in Pregnancy to Express Breastmilk In
    Articles Advising women with diabetes in pregnancy to express breastmilk in late pregnancy (Diabetes and Antenatal Milk Expressing [DAME]): a multicentre, unblinded, randomised controlled trial Della A Forster, Anita M Moorhead, Susan E Jacobs, Peter G Davis, Susan P Walker, Kerri M McEgan, Gillian F Opie, Susan M Donath, Lisa Gold, Catharine McNamara, Amanda Aylward, Christine East, Rachael Ford, Lisa H Amir Summary Lancet 2017; 389: 2204–13 Background Infants of women with diabetes in pregnancy are at increased risk of hypoglycaemia, admission to a See Editorial page 2163 neonatal intensive care unit (NICU), and not being exclusively breastfed. Many clinicians encourage women with See Comment page 2167 diabetes in pregnancy to express and store breastmilk in late pregnancy, yet no evidence exists for this practice. We Judith Lumley Centre, School of aimed to determine the safety and efficacy of antenatal expressing in women with diabetes in pregnancy. Nursing and Midwifery, La Trobe University, Methods We did a multicentre, two-group, unblinded, randomised controlled trial in six hospitals in Victoria, Australia. Melbourne, VIC, Australia (Prof D A Forster PhD, We recruited women with pre-existing or gestational diabetes in a singleton pregnancy from 34 to 37 weeks’ gestation A M Moorhead RM, and randomly assigned them (1:1) to either expressing breastmilk twice per day from 36 weeks’ gestation (antenatal L H Amir PhD); Royal Women’s expressing) or standard care (usual midwifery and obstetric care, supplemented by support from a diabetes educator). Hospital, Parkville, VIC, Randomisation was done with a computerised random number generator in blocks of size two and four, and was Australia (Prof D A Forster, A M Moorhead, S E Jacobs MD, stratified by site, parity, and diabetes type.
    [Show full text]
  • Undergoing Prenatal Screening for Down's Syndrome
    European Journal of Human Genetics (2007) 15, 563–569 & 2007 Nature Publishing Group All rights reserved 1018-4813/07 $30.00 www.nature.com/ejhg ARTICLE Undergoing prenatal screening for Down’s syndrome: presentation of choice and information in Europe and Asia Sue Hall1, Lyn Chitty2, Elizabeth Dormandy1, Amelia Hollywood1, Hajo IJ Wildschut3, Albert Fortuny4, Bianca Masturzo5,Ji´ı Sˇantavy´6, Madhulika Kabra7, Runmei Ma8 and Theresa M Marteau*,1 1King’s College London, Institute of Psychiatry, Department of Psychology (at Guy’s), Health Psychology Section, London, UK; 2Clinical & Molecular Genetics, Institute of Child Health and UCLH, London, UK; 3Department of Obstetrics and Gynecology, Erasmus University Medical Centre, Rotterdam, The Netherlands; 4Department of Obstetrics & Gynaecology, Prenatal diagnosis Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain; 5Department of Obstetrics and Gynaecology, Prenatal Diagnosis Unit, Sant’Anna Hospital, Turin, Italy; 6Department of Medical Genetics & Fetal Medicine, University Hospital, Olomouc, Czech Republic; 7Genetics Subdivision, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India; 8Department of Obstetrics and Gynaecology, 1st Affiliated Hospital of Kunming Medical College, Yunnan, China To date, studies assessing whether the information given to people about screening tests facilitates informed choices have focussed mainly on the UK, US and Australia. The extent to which written information given in other countries facilitates informed choices is not known. The aim of this study is to describe the presentation of choice and information about Down’s syndrome in written information about prenatal screening given to pregnant women in five European and two Asian countries. Leaflets were obtained from clinicians in UK, Netherlands, Spain, Italy, Czech Republic, China and India.
    [Show full text]
  • Pathology and Pregnancy Congratulations As Everyone Will Tell You, Having a Baby Is One of Life’S Most Amazing and Enriching Experiences
    Pathology and Pregnancy Congratulations As everyone will tell you, having a baby is one of life’s most amazing and enriching experiences. Whether this is your first pregnancy or you’ve done it all before, pathology tests will play a vital role in your care and progress. Every pregnancy is different. As your pregnancy progresses and your baby develops, you can expect to have some relevant tests. This booklet sets out the tests and gives you information about what they tell us. Some will be a matter of routine and others may be suggested if your doctor or midwife thinks they are necessary. Some will be done regularly every few weeks, others only at certain times when your baby is at a particular developmental milestone. It’s our job to perform your tests. You are most likely to meet us through our caring and friendly blood collectors. Behind them, back in the lab, are our pathologists and scientists, the medical experts who do the testing and interpret the results. They help your doctor make the important decisions. All of us at Sullivan Nicolaides Pathology are part of your healthcare team, and we are with you every step of the way. We wish you a happy pregnancy and a safe delivery 2 TESTS DURING PREGNANCY Not all tests are routine; some may only be performed if indicated. TIMING TESTS First Trimester MOTHER’S HEALTH Pregnancy test Full blood count including haemoglobin and platelet count Blood group and antibody testing Iron studies Blood glucose Vitamin D level Urine test for glucose and protein Pap smear INFECTIOUS DISEASES Rubella (German
    [Show full text]
  • BMFMS: Pregnancy Outcome NHS Education Board for Scotland Tendering a Project
    Poster presentations (range 10–33 days, mean 19 days, p.0.05). The rate at which the were: Maternal Postnatal Attachment Questionnaire (MPAQ), side-lying group achieved three, four or five feeds per day Neonatal Perception Inventory (NPI), Parental Stress Index Short was, however, more rapid than the rate seen in the semi-upright Form (PSI-SF), Beck Anxiety Inventory (BAI), Beck Depression Arch Dis Child Fetal Neonatal Ed: first published as on 10 June 2008. Downloaded from group. Inventory (BDI) and Gordon-Personal Profile Inventory (GPP-I) Side-lying was well accepted by both parents and nursing staff. (time 1 only). This pilot study will inform the design of further necessary research Results: At time 1, some baseline characteristics between the to examine the potential benefits of this approach to an important intervention and the control group were significantly different with and common problem. regard to gestational age at birth (more preterm in the KMC group), days in intensive care (more days in the KMC group) and mothers’ BDI score (higher in the TC group). All of these were considered as PN.02 A DEVELOPMENT IN SCOTTISH QUALIFICATION AND CREDIT covariates in the statistical analysis. At time 2, KMC mothers were FRAMEWORK LEVEL 10 NEONATAL NURSING EDUCATION IN less rejective (MPAQ) towards their infants (F (1, 42) 9.56; SCOTLAND: INNOVATION AND COLLABORATION p = 0.004) and less preoccupied (NPI) in caring for their infants (F (1, 42) 5.06; p = 0.031) than TC mothers. The parenting stress level 1C Greig, 2SL Alexander, 1M Lobban. 1Napier University, Edinburgh, UK; 2Glasgow Caledonian University, Glasgow, UK changed between times 1 and 2: TC mothers only experienced a significant increase from time 1 (mean 42.77) to time 2 (49.27) (F (1, Two reports recommended a structured career pathway for 22) 7.570; p,0.01).
    [Show full text]
  • Prenatal Testing & Information
    Prenatal Testing & Information ABOUT DOWN SYNDROME Helpful Resources Introduction Pregnancy can be an exciting time...and one that can produce Every woman and every pregnancy is different. Pediatricians, genetic emotions and many questions. Will my baby be a boy or a girl? Who counselors, family members, friends, spiritual advisers and others will he or she look like the most? Is my baby healthy? To help answer can assist a pregnant woman who received a prenatal diagnosis of Down syndrome. these questions, your doctor or healthcare provider may offer you a variety of testing options during your pregnancy. EARLY INTERVENTION, EDUCATIONAL AND EMOTIONAL SUPPORTS Woodbine House Books on Down Syndrome www.woodbinehouse.com/down-syndrome.29.0.0.2.htm MEDICAL CARE American Academy of Pediatrics, “Health Supervision for Children with Down Syndrome”: http://pediatrics.aappublications.org/ content/128/2/393.full.pdf Anna & John J. Sie Center for Down Syndrome, “Pediatric Guideline Record Tool”: http://www.globaldownsyndrome.org/pediatrics- record-sheet/ NEW & EXPECTANT PARENTS • www.downsyndrometest.org • www.ndsccenter.org/resources/new-and-expectant-parents • www.downsyndromepregnancy.org • Babies with Down Syndrome: A New Parents’ Guide (book is available in English and Spanish) • The Parent’s Guide to Down Syndrome: Advice, Information, Inspiration, and Support for Raising Your Child from Diagnosis through Adulthood IF YOU HAVE QUESTIONS ABOUT YOUR PREGNANCY OR ABOUT DOWN SYNDROME, PLEASE CALL 1-888-960-1670 OR VISIT US AT WWW.DOWNSYNDROMETEST.ORG 1 2 Answering What is a “prenatal test” for Down syndrome? Your Questions GENERALLY THERE ARE TWO types of tests (screening Should I have testing? tests and diagnostic tests) that you can have while you are pregnant to help determine if your baby has Down syndrome or another THE DECISION WHETHER TO HAVE a prenatal chromosome condition.
    [Show full text]
  • The Identification and Validation of Neural Tube Defects in the General Practice Research Database
    THE IDENTIFICATION AND VALIDATION OF NEURAL TUBE DEFECTS IN THE GENERAL PRACTICE RESEARCH DATABASE Scott T. Devine A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the School of Public Health (Epidemiology). Chapel Hill 2007 Approved by Advisor: Suzanne West Reader: Elizabeth Andrews Reader: Patricia Tennis Reader: John Thorp Reader: Andrew Olshan © 2007 Scott T Devine ALL RIGHTS RESERVED - ii- ABSTRACT Scott T. Devine The Identification And Validation Of Neural Tube Defects In The General Practice Research Database (Under the direction of Dr. Suzanne West) Background: Our objectives were to develop an algorithm for the identification of pregnancies in the General Practice Research Database (GPRD) that could be used to study birth outcomes and pregnancy and to determine if the GPRD could be used to identify cases of neural tube defects (NTDs). Methods: We constructed a pregnancy identification algorithm to identify pregnancies in 15 to 45 year old women between January 1, 1987 and September 14, 2004. The algorithm was evaluated for accuracy through a series of alternate analyses and reviews of electronic records. We then created electronic case definitions of anencephaly, encephalocele, meningocele and spina bifida and used them to identify potential NTD cases. We validated cases by querying general practitioners (GPs) via questionnaire. Results: We analyzed 98,922,326 records from 980,474 individuals and identified 255,400 women who had a total of 374,878 pregnancies. There were 271,613 full-term live births, 2,106 pre- or post-term births, 1,191 multi-fetus deliveries, 55,614 spontaneous abortions or miscarriages, 43,264 elective terminations, 7 stillbirths in combination with a live birth, and 1,083 stillbirths or fetal deaths.
    [Show full text]